Dr. Peters Named Head of the Michigan Cancer Foundation

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 6
Volume 4
Issue 6

DETROIT--William P. Peters, MD, PhD, noted for pioneering outpatient ABMT for breast cancer at Duke University (see story on page 9), has been named president and CEO of the Michigan Cancer Foundation and director of the Meyer L. Prentis Comprehensive Cancer Center of Metropolitan Detroit, effective July 1. He will also serve as associate dean for cancer programs at Wayne State University School of Medicine.

DETROIT--William P. Peters, MD, PhD, noted for pioneering outpatientABMT for breast cancer at Duke University (see story on page 9),has been named president and CEO of the Michigan Cancer Foundationand director of the Meyer L. Prentis Comprehensive Cancer Centerof Metropolitan Detroit, effective July 1. He will also serveas associate dean for cancer programs at Wayne State UniversitySchool of Medicine.

Articles in this issue
IDEC-C2B8 Antibody Is in Phase III Testing for B-Cell Lymphoma
Dr. Peters Named Head of the Michigan Cancer Foundation
Broad-Spectrum Sunscreens Block UVA and UVB
Trials of AccuSite Injectable Gel From Matrix Begin in Basal Cell Ca
Outpatient ABMT at Duke Leads to Savings
Russia Is Taking First Steps to Deliver Its Health-Care System Out of Chaos
Algorithm Optimizes Value of CA125 II Screening for Ovarian Ca
Better Ovarian Cancer Outcome With IP Cisplatin
Counseling Must Go Hand in Hand With Genetic Testing for Breast Cancer
Epirubicin Effective But Toxicity Is Increased
Aggressive 16-Week Multidrug Regimen Improves Breast Cancer Survival
Telomerase Appears to Play a Role in Cancer Cell Immortality
Changes in Health-Care Delivery Could Alter System of Medical Ethics
Researchers Seek Pleural Effusions And Tissue to Create MCB Cell Lines
NIH Granted Gene Therapy Patent
Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
2 experts in this video
Related Content
EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

EC Approves Brentuximab Vedotin Combo in Late-Stage Hodgkin Lymphoma

Tim Cortese
June 3rd 2025
Article

In patients with advanced Hodgkin lymphoma, BrECADD was noninferior to eBEACOPP chemotherapy and demonstrated improved progression-free survival.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.

Ziftomenib Shows MRD-Negative Responses in Pretreated NPM1+ AML

Ashling Wahner
June 3rd 2025
Article

The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

Silas Inman
June 3rd 2025
Article

A combination of BCG and mitomycin offers a comparable treatment option to BCG monotherapy for NMIBC, potentially lessening the impact of global BCG shortages.

Daratumumab Plus KRd May Be a New SOC Option in NDMM

Daratumumab Plus KRd May Be a New SOC Option in NDMM

Tim Cortese
June 3rd 2025
Article

Daratumumab plus KRd improved MRD-negativity and PFS vs KRd alone in patients with newly diagnosed multiple myeloma.